Effect of Risperidone on Behavioral and Psychological Symptoms and Cognitive Function in Dementia
J Clin Psychiatry 2001;62:894-900
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Aims: This open-label study examined the
efficacy and tolerability of risperidone in the treatment of
aggression, agitation, and psychotic symptoms in dementia. The
influence of risperidone on cognitive function was also assessed
under conditions reflecting normal, daily clinical care.
Method: A total of 34 hospital inpatients and
outpatients (mean age = 76 years) with DSM-IV dementia disorders
were treated with flexible doses of risperidone (0.5-2 mg/day)
for 8 weeks. Assessments, conducted at baseline and after weeks 4
and 8, included the Clinical Global Impressions scale (CGI) and
Neuropsychiatric Inventory (NPI) ratings. Cognitive function
assessments included the Mini-Mental State Examination (MMSE) and
specific measures of cognition (Age Concentration Test [AKT] and
Brief Syndrome Test [SKT]). Frequency of extrapyramidal symptoms
(EPS) was measured according to the Extrapyramidal Symptom Rating
Results: At the end of the study, 50% of
patients (N = 17) were receiving risperidone,1 mg/day, 18% (N =
6) were receiving 0.5 mg/day, and 32% (N = 11) received > 1
mg/day (mean dose at endpoint = 1.1 mg/day). An improvement in
symptoms, as measured by the CGI-Global Impression of Change
scale, was reported for 82% of patients (N = 28) (59% [N = 20]
much or very much improved). The frequency and severity of
delusions, hallucinations, agitation/aggression, and irritability
decreased as measured by the NPI. Multiplication of frequency and
severity scores revealed a significant decline during the course
of treatment (p < .001, end of study vs. baseline). Caregiver
responses on the NPI also showed an improvement, with the mean ±
SD total score decreasing from 24.2 ± 7.3 at baseline to 21.2 ±
6.3 at study end (p = .002). MMSE, AKT, and SKT results indicated
that there was no decrease in cognitive function during the
study. Risperidone treatment was well tolerated, and no
clinically relevant changes in EPS, vital signs, or weight were
Conclusion: During treatment with low-dose
risperidone, behavioral and psychological symptoms improved
overall in 34 patients with dementia, and cognitive function was
maintained throughout the treatment period.